Pinaverium

Summary

Pinaverium (CHEMBL1909324) is an approved small molecule (ATC A03AX04); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AX04
• Indications: 1 condition
• Clinical trials: 7
• Chemistry: 511.5 Da · C26H41BrNO4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1909324
Name	Pinaverium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	40704
ATC	A03AX04
Molecular formula	C26H41BrNO4+
Molecular weight	511.5
InChIKey	DDHUTBKXLWCZCO-UHFFFAOYSA-N

SMILES: CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C

IUPAC name: 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium

Also known as: Pinaverium, Pinaverium cation, Pinaverium ion, PINAVERIUM, pinaverium, PINAVERIUM BROMIDE

Parent form; salt/anhydrous children: CHEMBL1909298

Patent coverage: 171 distinct patent families (565 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Voltage-dependent L-type calcium channel subunit alpha-1C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CACNA1C	5.76	IC50	1750	nM	CHEMBL_ACT_15373274

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
Not specified	5
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02173964	PHASE4	COMPLETED	Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose)
NCT02833103	PHASE4	UNKNOWN	Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction
NCT06936800	Not specified	ENROLLING_BY_INVITATION	Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP)
NCT07172139	Not specified	NOT_YET_RECRUITING	Transcranial Magnetic Stimulation and Pharmacologic/Probiotic Interventions for Diarrhea-Predominant IBS
NCT01641224	Not specified	UNKNOWN	A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome
NCT02330029	Not specified	UNKNOWN	Pinaverium and Herbs for Irritable Bowel Syndrome Treatment: an Onset and Offset Study (PHIBEST)
NCT02882451	Not specified	UNKNOWN	Impact of Pinaverium Bromide on Bile Duct and Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).